South Australian Institute of Ophthalmology, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia.
South Australian Institute of Ophthalmology, The University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia; Tun Hussein Onn National Eye Hospital, Selangor, Malaysia.
Surv Ophthalmol. 2022 Sep-Oct;67(5):1540-1546. doi: 10.1016/j.survophthal.2022.06.002. Epub 2022 Jun 9.
Intracameral phenylephrine is commonly used in ophthalmic surgery as an alternative or supplement to mydriatic eye drops; hence, the importance of an evidence-based understanding of its risk-benefit profile is vital. We performed a comprehensive search in the PubMed, Google Scholar, and Cochrane databases for published studies and case reports relating to the use of intracameral phenylephrine. Articles from 1958 to 2021 with the following keywords were used: "intracameral phenylephrine," "intracameral mydriatics," "phenylephrine," "pupil dilation," "complications." Intracameral phenylephrine was first used in 2003 as an alternative to topical mydriatics. Since then, it is being increasingly used with a variety of benefits, including rapid onset of mydriasis, and cost-effectiveness. There are various case reports, however, of ocular and systemic complications associated with intracameral phenylephrine such as generation of free radicals, toxic anterior segment syndrome, inconsistent pupillary dilation during surgery, and ventricular fibrillation. Alternatives to intracameral phenylephrine such as iris hooks, a Malyugin ring, intracameral epinephrine, and intracameral tropicamide were compared with intracameral phenylephrine. Intracameral phenylephrine appears to have a good safety profile.
眼内注射苯肾上腺素通常在眼科手术中用作散瞳滴眼液的替代品或补充剂；因此，基于证据了解其风险-收益概况至关重要。我们在 PubMed、Google Scholar 和 Cochrane 数据库中进行了全面检索，以查找与眼内注射苯肾上腺素使用相关的已发表研究和病例报告。使用了以下关键词的 1958 年至 2021 年的文章：“眼内注射苯肾上腺素”、“眼内散瞳剂”、“苯肾上腺素”、“瞳孔散大”、“并发症”。眼内注射苯肾上腺素于 2003 年首次被用作局部散瞳剂的替代品。从那时起，它越来越多地被用于各种益处，包括快速散瞳作用和成本效益。然而，有各种与眼内注射苯肾上腺素相关的眼内和全身并发症的病例报告，例如自由基的产生、前节毒性综合征、手术期间瞳孔扩张不一致和心室颤动。与眼内注射苯肾上腺素相比，虹膜钩、Malyugin 环、眼内肾上腺素和眼内托品酰胺等替代品也被进行了比较。眼内注射苯肾上腺素似乎具有良好的安全性。
